Thermo Fisher Scientific在2025年第四季度的盈利超出预期，提升了其股票和股息，而内部人士则抛售了股票。 Thermo Fisher Scientific beat earnings expectations in Q4 2025, boosting its stock and dividend while insiders sold shares.

2026年1月29日, Thermo Fisher Science报告Q4收入丰厚, 达6.57 EPS和122.2亿美元的收入, 超过预期。 Thermo Fisher Scientific reported strong Q4 earnings on January 29, 2026, with $6.57 EPS and $12.22 billion in revenue, surpassing expectations. 该公司的股票升至514.20美元,市场上限为193.19亿美元,分析师保持了“机动购买”的一致评级。 The company's stock rose to $514.20, with a market cap of $193.19 billion, and analysts maintained a "Moderate Buy" consensus rating. Westpac的股份增加了179%,而RKL财富管理公司则将其持有量减少了14.5%。 Westpac increased its stake by 179%, while RKL Wealth Management reduced its holding by 14.5%. 内幕人士在90天内出售了98 000多股,尽管该公司继续股票回购,并将季度红利提高到每股0.47美元。 Insiders sold over 98,000 shares in 90 days, though the firm continues share repurchases and raised its quarterly dividend to $0.47 per share.